The biopharmaceutical company which is a spin-out from the University of Bath relocates to the North-East of England.
IP Group, a specialist intellectual property investor, has invested £2m ($3.1m) in Glythera, a biopharmaceutical company specialised in protein functionalisation. The company is a spin-out from the University of Bath. The deal follows an initial £600,000 investment between IP Group and its fund, the Finance for Business North East Technology Fund. The following two investments…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
